Navarixin

Drug Profile

Navarixin

Alternative Names: MK-7123; PS-291822; SCH 527123; SCH 5271234

Latest Information Update: 29 May 2015

Price : $50

At a glance

  • Originator Pharmacopeia; Schering-Plough
  • Developer Ligand Pharmaceuticals; Merck & Co
  • Class Anti-inflammatories; Benzamides; Cyclobutanes
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 22 May 2013 Efficacy data from a phase II trial in Chronic obstructive pulmonary disease presented at the 109th International Conference of the American Thoracic Society (ATS-2013)
  • 01 Dec 2011 Merck terminates phase II trial in Chronic obstructive pulmonary disease in European Union, Russia, Ukraine, Australia, Canada, Mexico, Argentina, Chile, Peru and Venezuela (NCT01006616)
  • 23 Dec 2009 Ligand Pharmaceuticals has been acquired by Neurogen Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top